Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-05-12 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various adjustments and approvals related to the company's stock incentive plans, including restricted stock and stock options. It references compliance with laws, company articles, and shareholder authorizations. The content focuses on governance matters related to stock incentive plans and approvals by the board and shareholders. It does not contain financial statements or earnings data, nor is it a report or announcement of financial results. It is a governance-related document expressing independent directors' opinions on board meeting matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2021-05-12 Chinese
关于调整2016年限制性股票激励计划预留授予部分回购价格的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the adjustment of the repurchase price of reserved grants under the 2016 restricted stock incentive plan of the company. It includes extensive background on the stock incentive plan, board and supervisory meetings, independent director opinions, legal opinions, and the rationale for the price adjustment. The content focuses on corporate governance and management decisions related to stock incentive plans rather than financial results or earnings. It is not a full annual or interim report, nor an earnings release, nor a proxy or voting announcement. It is also not a regulatory certification or a simple report publication announcement. The document is a formal announcement of a management decision related to stock incentive plan adjustments, which fits best under Board/Management Information (MANG).
2021-05-12 Chinese
2020年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2020 annual equity distribution plan (dividend distribution) approved at the 2021 shareholders' meeting. It details the dividend per share, record date, ex-dividend date, and related procedures. The document is relatively short (2249 characters) and focuses on dividend payment details rather than presenting a full annual report or financial statements. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a proxy solicitation or voting result announcement. The content matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2021-04-30 Chinese
2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2020 Annual General Meeting (AGM) resolutions of the company. It details the date and method of the meeting, attendance, and the voting results on various agenda items including approval of the 2020 annual report, financial statements, profit distribution plan, and remuneration plans. It also includes a legal opinion confirming the validity of the meeting and voting process. The document does not contain the full annual report or financial statements themselves but reports on the resolutions passed at the AGM. The length is about 5117 characters, which is consistent with an announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-04-21 Chinese
国浩律师（深圳）事务所关于公司2020年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It details the legality and validity of the AGM's convening, attendance, agenda, voting procedures, and results. The document does not contain the actual annual report or financial statements but rather provides a legal opinion on the AGM process and outcomes. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting. The document length (8006 characters) and content confirm it is not a brief announcement or a certification but a substantive legal opinion related to the AGM.
2021-04-21 Chinese
关于2017年股票期权激励计划首次授予股票期权第三个行权期采用自主行权模式的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the exercise of stock options under a 2017 stock option incentive plan by the company. It details the number of options exercisable, exercise price, exercise period, and the impact on share capital and financials. It is a notification about a capital change event related to stock options being exercised, not a full financial report or earnings release. The document is relatively short (2429 characters) and focuses on the stock option exercise event and related share capital impact. This fits the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues or capital changes such as stock option exercises.
2021-04-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.